What Is Gramicidin S? Definition and What Research Reports

Definition

Gramicidin S is a cyclic decapeptide antibiotic — a ring of ten amino acids, conventionally written as cyclo(-Val-Orn-Leu-D-Phe-Pro-)₂, meaning the same five-residue sequence repeats twice around a closed macrocycle. It belongs to the family of cationic amphipathic antimicrobial peptides: the two ornithine side chains carry positive charge, while the valine, leucine and phenylalanine side chains form a hydrophobic face. It is produced by soil bacteria of the Aneurinibacillus group (historically described under Bacillus brevis). Despite the shared name, gramicidin S is chemically and structurally distinct from the linear gramicidins (gramicidin A/D), which form ion channels; the "S" is a separate cyclic molecule with its own history and literature.

Where It Comes From

Gramicidin S is not made by ribosomes. It is assembled by non-ribosomal peptide synthetases (NRPS), large multi-domain enzyme assembly lines in which adenylation domains select and activate each amino acid building block. A 2023 methods chapter described chemoproteomic profiling of adenylation domain function in gramicidin S-producing non-ribosomal peptide synthetases, using activity-based probes to read out which domains were engaged (PMID 37184700). Because the peptide is a fermentation product, downstream recovery is itself a research topic: a 2024 bioengineering paper reported an efficient one-step extraction process for gramicidin S from Aneurinibacillus aneurinilyticus biomass (PMID 39267904).

Structure and Why It Is Studied as a Scaffold

The gramicidin S macrocycle folds into an antiparallel β-sheet closed at each end by a β-turn, with the proline and D-phenylalanine residues occupying the turn positions. That rigid, well-defined fold is a large part of why chemists use the molecule as a model system. Crystallographic work published in 2001 examined N,N-bis(trichloroacetyl) and N,N-bis(m-bromobenzoyl) derivatives of gramicidin S and reported antiparallel pleated β-sheets in the resulting crystal structures (PMID 11673869).

The turn region has been a deliberate target for redesign. A 2023 study in Bioorganic Chemistry described "β-turn editing" in gramicidin S, replacing the proline α-carbon with a stereodynamic nitrogen and assessing the impact of that substitution on activity (PMID 37300963). Other groups have swapped in unnatural building blocks entirely: a 2020 paper in ChemMedChem reported the development of therapeutic gramicidin S analogues bearing "plastic" β,γ-diamino acids (PMID 32233075).

How the Term Is Used in Peptide Research

In the literature, "gramicidin S" generally appears in one of four roles:

• As a named antibiotic. It is one of the earliest described peptide antibiotics, frequently discussed alongside tyrocidine in reviews of membrane-active antibacterials.
• As a medicinal-chemistry scaffold. Its small, rigid, symmetric ring makes it a convenient template for systematic substitution studies aimed at separating antibacterial activity from toxicity toward mammalian cells.
• As a model membrane-active peptide. Biophysical work uses it to probe how cationic amphipathic peptides adsorb to and permeabilise lipid bilayers.
• As an analytical standard. Its stable, well-characterised ion chemistry makes it a common test molecule in mass spectrometry; a 2017 study used gramicidin S and ubiquitin ions in experiments on reactive landing onto activated self-assembled monolayer surfaces (PMID 28290125).

What the Published Literature Reports

Antibacterial mechanism

A 2018 paper in mBio examined what the authors called the multifaceted antibacterial mechanisms of the pioneering peptide antibiotics tyrocidine and gramicidin S, indicating that the activity of these compounds was not attributable to a single membrane effect alone (PMID 30301848). This mechanistic framing — membrane disruption plus additional downstream consequences — is the background assumption behind most subsequent analogue work.

Analogue programmes and resistant organisms

Much of the recent literature concerns derivatives rather than the parent peptide. A 2024 paper in the Journal of Medicinal Chemistry described a new gramicidin S analogue that the study reported as having potent antibacterial activity with negligible haemolytic toxicity (PMID 38900970). A 2025 paper in Antibiotics reported broad-spectrum gramicidin S derivatives with potent activity against multidrug-resistant Gram-negative ESKAPE pathogens (PMID 40426491). These were laboratory characterisations of new chemical entities, not clinical trials.

Exploratory antiviral work

A 2022 report in Scientific Reports evaluated gramicidin S and melittin as potential anti-viral therapeutic peptides in the context of SARS-CoV-2 infection (PMID 35236909). The work was preclinical and exploratory; it did not establish a clinical treatment.

Membrane interactions with other drugs

Researchers have also used gramicidin S to probe co-operative effects in lipid bilayers. A 2021 study in Membranes reported that the antimicrobial peptide gramicidin S enhanced the membrane adsorption and ion pore formation potency of chemotherapy drugs in model lipid bilayers (PMID 33808204). That was a biophysical model-membrane experiment rather than a study in animals or people.

Toxicity and Immunogenicity: What Studies Report

The recurring liability discussed in the gramicidin S literature is activity against mammalian membranes, most often measured as haemolysis of red blood cells. This is why analogue papers report haemolytic toxicity alongside antibacterial potency: the 2024 Journal of Medicinal Chemistry analogue was characterised specifically as combining potent antibacterial activity with negligible haemolytic toxicity (PMID 38900970), and the β,γ-diamino acid analogue programme was likewise framed around developing therapeutically useful versions of the scaffold (PMID 32233075). Immune recognition has been assessed separately: a 2025 paper in RSC Medicinal Chemistry reported an in vitro evaluation of the immunogenic potential of gramicidin S and its photocontrolled analogues (PMID 40270993). No human dosing information is summarised on this page, and none should be inferred from these laboratory studies.

Quick Reference

What This Entry Does Not Cover

This glossary entry is definitional. It does not describe human dosing, administration routes, schedules or outcomes, because the verified literature summarised here consists of chemistry, microbiology, biophysics and preclinical work rather than controlled human trials. Claims that gramicidin S or its analogues treat any human infection or viral illness are not supported by the studies cited above, which reported laboratory findings only. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or decision.

References

• The Multifaceted Antibacterial Mechanisms of the Pioneering Peptide Antibiotics Tyrocidine and Gramicidin S (mBio, 2018)
• Chemoproteomic Profiling of Adenylation Domain Functions in Gramicidin S-Producing Non-ribosomal Peptide Synthetases (Methods in Molecular Biology, 2023)
• Efficient one step extraction process of Gramicidin S from Aneurinibacillus aneurinilyticus biomass (Frontiers in Bioengineering and Biotechnology, 2024)
• Antiparallel pleated beta-sheets observed in crystal structures of N,N-bis(trichloroacetyl) and N,N-bis(m-bromobenzoyl) gramicidin S (Archives of Biochemistry and Biophysics, 2001)
• β-Turn editing in Gramicidin S: Activity impact on replacing proline α-carbon with stereodynamic nitrogen (Bioorganic Chemistry, 2023)
• Development of Therapeutic Gramicidin S Analogues Bearing Plastic β,γ-Diamino Acids (ChemMedChem, 2020)
• A New Gramicidin S Analogue with Potent Antibacterial Activity and Negligible Hemolytic Toxicity (Journal of Medicinal Chemistry, 2024)
• Broad-Spectrum Gramicidin S Derivatives with Potent Activity Against Multidrug-Resistant Gram-Negative ESKAPE Pathogens (Antibiotics, 2025)
• Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection (Scientific Reports, 2022)
• The Antimicrobial Peptide Gramicidin S Enhances Membrane Adsorption and Ion Pore Formation Potency of Chemotherapy Drugs in Lipid Bilayers (Membranes, 2021)
• In vitro evaluation of the immunogenic potential of gramicidin S and its photocontrolled analogues (RSC Medicinal Chemistry, 2025)
• Reactive Landing of Gramicidin S and Ubiquitin Ions onto Activated Self-Assembled Monolayer Surfaces (Journal of the American Society for Mass Spectrometry, 2017)